Citations

Clear

163 citation(s) found for "Sharp, H L".

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer
Longoria, Ossian , Rekowski, Jan , Beije, Nick , Efstathiou, Eleni, Castellano, Daniel , Fizazi, Karim , Sharp, Adam , Macé, Sandrine , Geffriaud-Ricouard, Christine, Wenstrup, Richard , Wit, Ronald de , Bono, Johann S. de , de Bono, Johann , Gupta, Santosh , Pantel, Klaus , Sternberg, Cora N , Tombal, Bertrand , Sartor, Oliver

Mayo Clinic

JCI Insight | November 4, 2025 | Volume: 10 | Issue: 24 | Pages: No page available

10.1172/jci.insight.196505 | PMID 41186991 Get It

BACKGROUND Predictive biomarkers to guide chemotherapy decisions for metastatic castration–resistant prostate cancer (mCRPC) are lacking. Preclinical studies indicate that circulating tumor cell (CTC) studies of chromosomal instability (CTC-CIN) can predict taxane resistance. METHODS The CARD trial randomized individuals with mCRPC progressing within a year of treatment with an androgen receptor pathway inhibitor (ARPI; enzalutamide or abiraterone acetate plus prednisolone/prednisone) to cabazitaxel or the alternative ARPI. As a preplanned biomarker analysis, CTCs were isolated from blood samples obtained at baseline, cycle 2, and the end of treatment. Associations between baseline CTC and CTC-CIN counts with imaging-based progression-free survival (ibPFS), overall survival (OS), time to prostate-specific antigen (PSA) progression, RECIST 1.1 objective response rate (ORR), and PSA 50 response rate were assessed. RESULTS High baseline CTC-CIN counts significantly associated with worse OS after adjustment for confounding variables (median OS, 15.3 vs. 8.9 months; univariate HR, 2.16; 95% CI, 1.52–3.06; P < 0.001; multivariate HR, 1.56; 95% CI, 1.01–2.43; P = 0.047). Detectable CTC-CIN counts at baseline may predict a lack of ibPFS and OS benefit when comparing cabazitaxel with ARPI. CONCLUSION This preplanned analysis of biomarker data from the CARD trial confirms that CTC-CIN counts are a clinically useful prognostic and predictive biomarker of taxane resistance in mCRPC. Detectable CTC-CIN at baseline defines a patient subpopulation with unmet clinical needs in which alternative therapeutics should be tested. TRIAL REGISTRATION ClinicalTrials.gov number NCT02485691. FUNDING Funded by Sanofi and Epic Sciences.
Abstract 4361649: Polysocial Risk Scores and Genetic Risk Factors Are Independently and Additively Associated with Cardiometabolic Diseases Across Self-Identified Race/Ethnicity Groups
Hamed, Marwan , Etheridge, Bethany, Espinoza, Angelica, Hakonarson, Hakon, Irvin, Ryan, Khan, Atlas , Namjou, Bahram , Landry, Latrice , Limdi, Nita A. , Sabatello, Maya , Tiwari, Hemant , Walunas, Theresa L. , Wei, Wei‐Qi, Wiesner, Georgia L. , Rowley, Robb , Manolio, Teri A. , Sharp, Richard R. , Kullo, Iftikhar, Sharp, Richard R , Walunas, Theresa L , Naderian, Mohammadreza , Smith, Johanna L. , Dikilitas, Ozan , Brokamp, Cole , Chaiyachati, Barbara H. , Chisholm, Rex L. , Clayton, Ellen Wright , Connolly, John J. , Davis, Brittney H. , Feng, QiPing , Hakonarson, Hakon, Holm, Ingrid A. , Jarvik, Gail P. , Kottyan, Leah C. , Luo, Yuan , Rasmussen‐Torvik, Laura J. , Tiwari, Hemant

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4361649 Get It

Background: Susceptibility to cardiometabolic diseases (CDs) is shaped by genetic, socio-environmental, and lifestyle factors. We evaluated the associations of disease-specific polysocial risk scores (PSSs)— derived from social determinants of health (SDOH) and lifestyle factors—and genetic risk factors with six CDs, across self-identified race/ethnicity (SIRE) groups in the eMERGE IV cohort. Methods: The six CDs included: atrial fibrillation, coronary heart disease, chronic kidney disease, hyperlipidemia, obesity, and type 2 diabetes. Disease-specific PSSs were developed using machine-learning models based on 65 SDOH and lifestyle factors. Participants were grouped based on their SIRE as Asian, Black, Hispanic/Latino, and White. We evaluated PSS distributions across SIRE groups. Genetic risk was assessed through disease-specific polygenic risk scores (PRSs), monogenic etiologies, and family history (FamHx). High PSS and high PRS were defined as the top 5th percentile. Associations were tested using multivariable logistic regression; model performance was assessed using the C-statistic. Results: Among 20178 participants (50±15 years, 68% female, 40% non-White), the most frequently associated PSS components were physical activity, sleep, self-perceived health, and income. PSS distributions varied across SIRE groups, with Whites having the lowest and Black and Hispanic/Latinos the highest scores for most CDs (Figure 1). All PSSs were significantly associated with their respective CDs, independent of confounders (OR per 1 SD increase: 1.19–2.68; Figure 2-A). No significant interactions were observed between PSSs and PRSs or monogenic etiologies. However, significant interactions were noted between PSSs and FamHx for CKD and obesity. PSS and PRS effects on the odds of CDs were independent (Figure 2-B) and additive (Figure 2-C). Incorporating PSSs into models that included clinical and genetic risk factors improved predictive performance of risk prediction models (Figure 3). Conclusion: PSSs, reflecting socio-environmental and lifestyle disadvantage, varied significantly across SIRE groups and were associated with risk of six CDs, independent of and additive to PRS. Given the substantial variation in socio-environmental and lifestyle risks across SIRE groups, integrating these factors into risk prediction models for CDs may help address health disparities and enhance preventive efforts, especially in marginalized populations.
Abstract 4361633: Incorporation of Genetic Risk Factors for Coronary Heart Disease into Clinical Risk Calculators Improved Risk Prediction in Three Major Race/Ethnicity Groups in the United States
Hamed, Marwan , Cortopassi, Joshua, Espinoza, Angelica, Irvin, Ryan, Limdi, Nita, McNally, Elizabeth M., Miller, Emily S. , Namjou, Bahram , Rowley, Robb , Tiwari, Hemant, Wei, Wei‐Qi, Khan, Atlas , Connolly, John, Wiesner, Georgia L. , Manolio, Teri A. , Sharp, Richard R. , Kullo, Iftikhar, Sharp, Richard R , Naderian, Mohammadreza , Smith, Johanna L. , Dikilitas, Ozan , Cortopassi, Josh , Feng, QiPing , Jarvik, Gail P. , Kottyan, Leah C. , Limdi, Nita A. , Puckelwartz, Megan J. , Tiwari, Hemant

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4361633 Get It

Background: We investigated the impact of genetic risk factors for coronary heart disease (CHD) -polygenic risk score (PRS), familial hypercholesterolemia (FH), and family history (FamHx)- on CHD risk estimates, across the age spectrum, in two diverse cohorts of US adults -eMERGE IV (eIV) and All of Us (AoU). Methods: CHD was defined as myocardial infarction, unstable angina, and coronary revascularization. Self-identified race/ethnicity (SIRE) was used as a population descriptor. We calculated a PRS for CHD (PRS CHD , PGS004698), ascertained FH as the presence of pathogenic/likely pathogenic variants in FH genes, and defined FamHx as early-onset CHD in first-degree relatives. We employed Pooled Cohort Equations (PCE) to estimate the 10y risk of CHD for adults ≥40y and modeled the association of conventional risk factors with CHD in adults <40y. AoU served as the training set, and eIV as the testing set. We analyzed the impact of PRS CHD and FamHx on CHD risk estimates by a) using multivariable logistic regression and Cox proportional hazard models, assessing discrimination and the extent of risk reclassification; and b) net benefit analysis and decision curves to assess the performance of prediction models across actionable thresholds. Results: We analyzed data for 19348 participants from eIV (age 50±15, 68% female, 41% non-White) and 239645 participants from AoU (age 55±17, 61% female, 48% non-White). Genetic risk factors were significantly associated with CHD. PRS CHD performance varied by SIRE groups, while FamHx was consistent. The effects of PRS CHD and FamHx on CHD were independent and additive (Figure 1). In adults ≥40y, incorporating PRS CHD and FamHx into PCE improved discrimination (C-statistic increased from 0.719 to 0.753; P -diff=9.1×10 -3 , Figure 2) and reclassified risk in 19% and 20% of participants at the 7.5% and 10% 10y CHD risk thresholds, respectively. Between the 7.5% and 10% 10y CHD risk thresholds, incorporating PRS CHD and FamHx into the PCE improved the net benefit of the risk prediction models across White, Black, and Hispanic/Latino groups (Figure 3). Conclusion: PRS CHD and FamHx were independently and additively associated with CHD in two large diverse cohorts in the US. Incorporating PRS CHD and FamHx into PCE improved risk discrimination, reclassified risk in a significant portion of participants, and improved net benefit of the PCE across all three major SIRE groups, motivating the addition of these factors to clinical risk calculators.
Using large language models to automate summarization of CT simulation orders in radiation oncology
Cao, Meiyun, Hu, S.X. , Sharp, Jason, Clouser, Edward , Lam, Louis, Ding, Xiaoning, Toesca, Diego Santos, Raulston, Brianne C, Lindholm, Wendy S., Patel, Samir H. , Vora, Sujay A., Wang, P. , Clouser, Edward Lee , Lam, Linda L, Wang, Peilong , Liu, Wei , Toesca, Diego A.S. , Hu, Shaw, Sharp, Jason, Holmes, Jason , Liu, Wei

Mayo Clinic

Journal of Applied Clinical Medical Physics | October 28, 2025 | Volume: 26 | Issue: 11 | Pages: No page available

10.1002/acm2.70310 | PMID 41144781 Get It

Abstract Background In the current clinical workflow of radiation oncology, therapists manually summarize the physician‐issued Computed Tomography (CT) simulation orders to prepare patients' CT simulations. This process increases the workload, introduces variability in documentation quality, and is prone to human errors. Purpose This study aims to address these challenges using a large language model (LLM) to automate the generation of summaries from the CT simulation orders and evaluate its performance. Methods A total of 607 CT simulation orders were collected from the Aria database at our institution. A locally hosted LLaMa 3.1 405B model, accessed via the Application Programming Interface (API) service, was used to extract keywords from the CT simulation orders and generate summaries. The downloaded CT simulation orders were categorized into seven groups based on treatment modalities and disease sites. For each group, a customized instruction prompt was developed collaboratively with therapists to guide the LLaMa 3.1 405B model in generating summaries. The ground truth for the corresponding summaries was manually derived by carefully reviewing each CT simulation order and subsequently verified by therapists. The accuracy of the LLM‐generated summaries was evaluated by therapists using the ground truth. Results Over 98% of the LLM‐generated summaries aligned with the ground truth in terms of accuracy. Our evaluations showed an improved consistency in format and enhanced readability from the LLM‐generated summaries compared to the corresponding therapist‐generated summaries. This automated approach demonstrated consistent performance across all groups, regardless of treatment modality or disease site. Conclusions This study demonstrated the high precision and consistency of the LLaMa 3.1 405B model in extracting keywords and summarizing CT simulation orders, suggesting that LLMs have great potential to assist in this task, reduce the workload of CT simulation therapists and improve radiation oncology workflow efficiency.
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
Cliff, Edward R. Scheffer , Pelaez, Guido D. , Wan, Fei , Iyengar, Varun , Zhou, Jihao , Chung, Kevin , Abdel-Razeq, Nayef , Allen, J. , Major, Ajay , Sharp, John , Gould, Patrick , Houshyar, Samin , Lynch, Ryan C. , Fleyshman, Michelle , Kidwell, Adam , Fenske, Timothy S. , Malakhov, Nikita , Mulvey, Erin , Nowakowski, Grzegorz S. , Torka, Pallawi , Russler‐Germain, David A. , Allen, Jessica , Epperla, Narendranath , Gould, Patrick , Cherng, Hua-Jay J , Houshyar, Samin , Wallace, Danielle S , Lynch, Ryan C , Kallam, Avyakta , Mei, Matthew , Merryman, Reid W , Fleyshman, Michelle , Rhodes, Joanna , Kidwell, Adam , Fenske, Timothy S , Malakhov, Nikita , Mulvey, Erin , Watkins, Marcus , Moustafa, Muhamad Alhaj , Hilal, Talal , Nowakowski, Grzegorz S , Wang, Yucai , Torka, Pallawi , Russler-Germain, David A , Major, Ajay , Sharp, John , Zhou, Jihao , Epperla, Narendranath , Cherng, Hua‐Jay J. , Wallace, Danielle , Kallam, Avyakta , Mei, Matthew , Merryman, Reid W. , Rhodes, Joanna , Watkins, Marcus P. , Moustafa, Muhamad Alhaj , Hilal, Talal , Wang, Yucai

Mayo Clinic

Clinical Cancer Research | October 27, 2025 | Volume: 32 | Issue: 1 | Pages: 159-168

10.1158/1078-0432.ccr-25-2392 | PMID 41143601 Get It

Abstract Purpose: Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial. However, when stratified by cell of origin (COO), polatuzumab seems to have greater efficacy in activated B-cell than germinal center B-cell (GCB) subtype disease. Most studies of polatuzumab used RNA expression to assess COO, whereas in routine clinical practice, the immunohistochemistry-based Hans algorithm is used. Experimental Design: To assess the impact of COO by immunohistochemistry on polatuzumab efficacy, we conducted a multicenter real-world study of adults with large B-cell lymphoma (LBCL) receiving polatuzumab from 2015 to 2024, split by receipt of polatuzumab in first-line versus relapsed/refractory settings. The primary endpoint was overall response rate (ORR) to polatuzumab-based treatment in GCB versus non-GCB relapsed/refractory LBCL. Results: Of 740 patients, 305 received polatuzumab in the first-line setting and 435 in the relapsed/refractory setting. In the relapsed/refractory cohort, the ORR in non-GCB versus GCB LBCL was 59.7% versus 36.3% [OR, 2.6; 95% confidence interval (CI), 1.77–3.84; P &lt; 0.0001], with a complete response rate of 35.7% versus 17.7% (OR, 2.6; 95% CI, 1.66–4.02; P &lt; 0.0001). Progression-free survival was longer for patients with non-GCB versus GCB COO (HR, 0.64; 95% CI, 0.5–0.83; P = 0.0006). In the first-line cohort, ORR, complete response rate, and progression-free survival were similar in non-GCB versus GCB LBCL, as hypothesized based on outcomes in the Pola-R-CHP arm of POLARIX, suggesting that the addition of polatuzumab overcomes the adverse risk of non-GCB COO in patients receiving R-CHOP. Conclusions: Based on these data, COO classification by the Hans algorithm is a strong predictor of polatuzumab efficacy in LBCL, informing real-world treatment decisions.
Mechanical and Electrical Properties of Respiratory Muscles
Sharp, John T. , Hyatt, Robert E.

Mayo Clinic

Comprehensive Physiology | October 23, 2025 | Volume: 1986 | Issue: 12S12 | Pages: 389-414

10.1002/j.2040-4603.1986.tb01102.x Get It

Abstract The sections in this article are: Basic Concepts—Review of Muscle Mechanics Muscle Fiber Types Mechanics of Muscle Electrical Properties of Skeletal Muscle Individual Respiratory Muscles and Their Properties General Considerations Diaphragm Intercostal Muscles Sternocleidomastoid and Scalenus Muscles Abdominal Muscles Other Respiratory Muscles Altered Respiratory Muscle Mechanical Properties in Disease Obstructive Lung Disease Diseases Characterized by Stiff Lungs Neuromuscular Diseases Severe Obesity
Patient comprehension of preemptive pharmacogenomic results
Pacyna, Joel E. , Olson, Janet E., Sharp, Richard R. , Bielinski, Suzette J. , Sharp, Richard R

Mayo Clinic

Pharmacogenomics | September 25, 2025 | Volume: 26 | Issue: 10-12 | Pages: 377-383

10.1080/14622416.2025.2565994 | PMID 40994430 Get It

Patients’ Concerns About Receiving Preemptive Pharmacogenomic Testing: Results from a Large, Longitudinal Survey of RIGHT Study Participants
Pacyna, Joel E. , Bielinski, Suzette J. , Olson, Janet E., Sharp, Richard R. , Sharp, Richard R , Bielinski, Suzette

Mayo Clinic

Journal of Personalized Medicine | June 17, 2025 | Volume: 15 | Issue: 6 | Pages: 258

10.3390/jpm15060258 | PMID 40559120 Get It

Background: As more healthcare institutions consider providing preemptive pharmacogenomic (PGx) testing to greater numbers of their patients, it will be important to consider the potential concerns patients may have about the generation of preemptive PGx information. To date, few studies have examined the nature and incidence of patient concerns about preemptive PGx testing. Methods: We conducted a longitudinal survey study of 5000 patients receiving preemptive PGx testing in the Mayo Clinic RIGHT study. We assessed patient concerns regarding issues of data confidentiality, cost implications, comprehension of results, and potential disruption of pre-existing medication regimens. Participants were surveyed before and after they received PGx results from the RIGHT study. Results: We achieved 92.8% and 74.4% response rates on the pre- and post-results surveys, respectively. Participants had low levels of concern about PGx testing overall. However, 25.5% of participants were “quite/extremely concerned” about insurance implications, and 30.1% were “quite/extremely” concerned about increased out-of-pocket costs for prescription medications that might result from PGx testing. These same concerns were significantly reduced on the post-results survey. Patients who initially expressed concerns regarding their ability to understand PGx results were more likely to report having difficulty understanding results on the post-results survey. Conclusions: Our findings suggest that as healthcare institutions look to increase preemptive PGx screening, attention should be given to potential concerns patients may have around such testing. Educational interventions aimed at supporting patient understanding of PGx results and addressing potential concerns will be important elements of a successful PGx program.
Comparing trends in telehealth utilization by medical oncology practices at Stanford Medicine and Mayo Clinic from 2019–2023.
Parameswaran, Vijaya , Miller, Marci, Grimm, Jessica, Gullerud, Rachel E., Fan, Winnie, Gibbons, Daniel J., Oyarzabal, Beatriz A., Lunde, Julianne J. , Rosengaus, Leah, Sharp, Christopher , Shah, Sumit , Haddad, Tufia C. , Grimm, Jessica, Coffey, Jordan , Harper, Sarah, Demaerschalk, Bart M. , Pritchett, Joshua C.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e13890 Get It

e13890 Background: Many oncology practices have reported continued use of telemedicine since onset of the COVID-19 pandemic. However, the future sustainability of telemedicine within oncology practices remains unclear, particularly because federal policies that enabled adoption in response to the public health emergency (PHE) have not been made permanent. Understanding similarities and differences in telemedicine utilization at high-volume oncology centers is crucial for shaping evidence-based policy that enables equitable access to oncology care across varying geographies. Methods: This is a cross-sectional, year-over-year, retrospective cohort analysis of trends in telemedicine utilization across all medical oncology clinical appointments conducted among adult patients (age >18) from January 2019 to December 2023 at Stanford Medicine Cancer Center (SM) – comprising multiple campuses in the California Bay Area – and the Mayo Clinic Comprehensive Cancer Center (MC) – a multiregional cancer practice with tertiary referral campuses in Minnesota, Florida, and Arizona, as well as community-based clinics throughout the Upper Midwest. Results: Both institutions exhibited a similar trend in telemedicine adoption over time. This was characterized by an initial surge in utilization following the PHE declaration in March 2020, followed by sustained utilization rates from 2021 to 2023. However, telemedicine use as a proportion of the overall practice differed significantly between institutions. At SM, the rate of telemedicine visits as a proportion of overall clinical practice was 60.3% (49,136/ 81,502) in 2021, 59.9% (52,247/ 87,215) in 2022, and 57.2% (55,007/ 96,163) in 2023. At MC, the proportion of telemedicine utilization was 12.8% in 2021 (23,873/186,086), 14.7% in 2022 (28,985/196,777), and 14.0% in 2023 (30,208/215,941). Deployment in the setting of new versus return visits also differed between institutions. In 2023, telemedicine accounted for 53.7% (6,440/11,998) of new and 57.7% (48,567/84,165) of return visits at SM, compared to 15.5% (3,359/21,728) and 13.8% (26,849/194,213) at MC. Additionally, while video visits were the predominant modality used to conduct telemedicine visits at both institutions from 2021 onward, in 2023 phone visits still made up 17.9% (5,394/30,208) of all telemedicine visits at MC, compared to just 5.4% (2,990/55,007) at SM. Conclusions: Stanford Medicine and Mayo Clinic exhibited a pattern of initial growth of telemedicine adoption in 2020, followed by sustained utilization from 2021-2023. We observed unique differences in the overall proportion, visit type deployment, and modality of telemedicine utilization between institutions. However, this study confirms telemedicine visits have remained a fixture of medical oncology care for many patients at these institutions since the COVID-19 pandemic.